Cilostazol, naftidrofuryl oxalate, pentoxifylline and inositol nicotinate for the treatment of intermittent claudication in people with peripheral arterial disease

  • Technology appraisal guidance
  • TA223
  • Published: 
Download guidance (PDF)

Appendix B: Sources of evidence considered by the Committee

A. The assessment report for this appraisal was prepared by the School of Health & Related Research Sheffield:

  • Squires H, Simpson E, Meng Y et al. Cilostazol, naftidrofuryl oxalate, pentoxifylline and inositol nicotinate for the treatment of intermittent claudication in people with peripheral arterial disease, October 2010

B. The following organisations accepted the invitation to participate in this appraisal as consultees and commentators. They were invited to comment on the draft scope, assessment report and the appraisal consultation document (ACD). Organisations listed in I and II were also invited to make written submissions and have the opportunity to appeal against the final appraisal determination.

I) Manufacturers/sponsors:

  • Otsuka

II) Professional/specialist and patient/carer groups:

  • British Cardiovascular Intervention Society (BCIS)

  • British Heart Foundation

  • Royal College of Nursing

  • Royal College of Physicians

III) Other consultees:

  • Department of Health

  • NHS Luton

  • NHS Salford

  • Welsh Assembly Government

IV) Commentator organisations (without the right of appeal):

  • Commissioning Support Appraisals Service

  • Department of Health, Social Services and Public Safety for Northern Ireland

  • Medicines and Healthcare products Regulatory Agency

  • NHS Quality Improvement Scotland

C. The following individual was selected from clinical specialist and patient expert nominations from the non-manufacturer/sponsor consultees and commentators. They participated in the Appraisal Committee discussions and provided evidence to inform the Appraisal Committee's deliberations. They gave their expert personal view on cilostazol, naftidrofuryl oxalate, pentoxifylline and inositol nicotinate by attending the initial Committee discussion and/or providing written evidence to the Committee. They were also invited to comment on the ACD.

  • Mr Constantinos Kyriakides, Consultant Vascular Surgeon, Barts and The London NHS Trust, nominated by Otsuka Pharmaceuticals – clinical specialist

D. Representatives from the following manufacturers/sponsors attended Committee meetings. They contributed only when asked by the Committee chair to clarify specific issues and comment on factual accuracy.

  • Otsuka